Mankind Pharma Limited

BSE:543904 Stock Report

Market Cap: ₹1.2t

Mankind Pharma Valuation

Is 543904 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543904 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 543904 (₹2938.25) is trading above our estimate of fair value (₹1413.02)

Significantly Below Fair Value: 543904 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543904?

Key metric: As 543904 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543904. This is calculated by dividing 543904's market cap by their current earnings.
What is 543904's PE Ratio?
PE Ratio55.6x
Earnings₹21.15b
Market Cap₹1.18t

Price to Earnings Ratio vs Peers

How does 543904's PE Ratio compare to its peers?

The above table shows the PE ratio for 543904 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.3x
500420 Torrent Pharmaceuticals
63.8x22.6%₹1.2t
CIPLA Cipla
27.3x7.6%₹1.2t
500124 Dr. Reddy's Laboratories
21.1x-1.1%₹1.1t
500257 Lupin
41.1x16.4%₹1.1t
543904 Mankind Pharma
55.6x15.5%₹1.2t

Price-To-Earnings vs Peers: 543904 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the peer average (38.3x).

Price to Earnings Ratio vs Industry

How does 543904's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.8xn/aUS$77.16m
524652 Ind-Swift
3xn/aUS$19.01m
No more companies available in this PE range
543904 55.6xIndustry Avg. 36.3xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 543904 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the Indian Pharmaceuticals industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is 543904's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543904 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio55.6x
Fair PE Ratio46.6x

Price-To-Earnings vs Fair Ratio: 543904 is expensive based on its Price-To-Earnings Ratio (55.6x) compared to the estimated Fair Price-To-Earnings Ratio (46.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 543904 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,938.25
₹2,814.88
-4.2%
11.9%₹3,300.00₹2,275.00n/a16
Dec ’25₹2,562.25
₹2,814.88
+9.9%
11.9%₹3,300.00₹2,275.00n/a16
Nov ’25₹2,690.55
₹2,469.87
-8.2%
15.2%₹3,300.00₹1,900.00n/a15
Oct ’25₹2,576.75
₹2,445.07
-5.1%
14.9%₹3,300.00₹1,900.00n/a15
Sep ’25₹2,488.00
₹2,297.57
-7.7%
10.1%₹2,760.00₹1,900.00n/a14
Aug ’25₹2,004.95
₹2,289.71
+14.2%
9.5%₹2,650.00₹1,900.00n/a14
Jul ’25₹2,162.15
₹2,302.87
+6.5%
10.3%₹2,650.00₹1,800.00n/a15
Jun ’25₹2,146.05
₹2,266.93
+5.6%
9.8%₹2,554.00₹1,800.00n/a14
May ’25₹2,366.00
₹2,199.77
-7.0%
10.9%₹2,520.00₹1,750.00n/a13
Apr ’25₹2,312.35
₹2,197.69
-5.0%
10.9%₹2,520.00₹1,750.00n/a13
Mar ’25₹2,147.70
₹2,184.17
+1.7%
11.2%₹2,520.00₹1,750.00n/a12
Feb ’25₹2,044.35
₹1,937.73
-5.2%
13.0%₹2,300.00₹1,433.00n/a11
Jan ’25₹1,977.65
₹1,859.00
-6.0%
10.7%₹2,140.00₹1,433.00₹2,887.4511
Dec ’24₹1,917.20
₹1,859.00
-3.0%
10.7%₹2,140.00₹1,433.00₹2,562.2511
Nov ’24₹1,744.50
₹1,853.73
+6.3%
11.0%₹2,190.00₹1,433.00₹2,690.5511
Oct ’24₹1,793.15
₹1,817.82
+1.4%
12.9%₹2,180.00₹1,433.00₹2,576.7511
Sep ’24₹1,725.45
₹1,838.60
+6.6%
12.8%₹2,180.00₹1,433.00₹2,488.0010
Aug ’24₹1,771.30
₹1,626.30
-8.2%
10.0%₹1,875.00₹1,425.00₹2,004.9510
Jul ’24₹1,706.30
₹1,648.67
-3.4%
9.5%₹1,875.00₹1,429.00₹2,162.159
Jun ’24₹1,398.15
₹1,484.50
+6.2%
3.1%₹1,539.00₹1,429.00₹2,146.054

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 09:16
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mankind Pharma Limited is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.